Company intelligence / Profile preview

PR Nine

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

PR9 is a pre-clinical stage biotechnology company focused on developing small molecule therapeutics for neurodegenerative diseases. The company specifically targets the restoration of progranulin (PGRN) levels, a key protein involved in lysosomal function and neuronal survival. Deficiencies in progranulin are a known genetic cause of frontotemporal dementia (FTD) and are implicated in other conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. PR9's approach aims to provide disease-modifying treatments by pharmacologically increasing the expression of PGRN to neuroprotective levels.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Bluefield InnovationsUniversity of California, San Francisco

Beyond the preview

Go deeper on PR Nine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PR Nine.

Explore the full profile